Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05866471 · ClinicalTrials.gov registry record · Phase 1
The ENHANCE Study: taVNS and Psilocybin
A Phase 1 study of Healthy and Psychedelic Experiences, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT05866471: Recruiting Phase 1 study of Healthy and Psychedelic Experiences, sponsored by University of Wisconsin, Madison.
NCT05866471 is a Phase 1 study of Healthy and Psychedelic Experiences that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 108 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05866471, a Phase 1 study of Healthy and Psychedelic Experiences, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared to sham taVNS or no VNS by allowing memory for insights gained during the psychedelic experience to remain vivid after they will have faded in subjects who receive psilocybin followed by sham taVNS or no VNS.
Primary Outcome
The MEM-Q is 31-item self-report scales designed to measure 10 phenomenological qualities of autobiographical memories: Vividness, Coherence, Accessibility, Time Perspective, Sensory Details, Visual Perspective, Emotional Intensity, Sharing, Distancing and Valence. Ratings are made on a 5-point Likert scale, ranging from 1 (strongly disagree) to 5 (strongly agree).
Conditions Studied
Interventions
- DRUG Psilocybin
- DEVICE Transcutaneous auricular Vagus Nerve Stimulation (taVNS)
- BEHAVIORAL Psychosocial Support Alone
- OTHER Sham taVNS
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-01-27 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
What NCT05866471 shows while recruiting
NCT05866471 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Psilocybin is the first listed.
NCT05866471 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05866471 about?
NCT05866471 is a clinical study titled "The ENHANCE Study: taVNS and Psilocybin". This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance the long-term beneficial behavioral effects of psilocybin when compared...
What is the current status of trial NCT05866471?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 108 participants. The study started on 2025-01-27. Estimated completion is 2028-01.
What conditions does trial NCT05866471 study?
This clinical trial studies the following conditions: Healthy, Psychedelic Experiences, Vagus Nerve Stimulation.
What interventions are being tested in trial NCT05866471?
The interventions under investigation include: Psilocybin (DRUG), Transcutaneous auricular Vagus Nerve Stimulation (taVNS) (DEVICE), Psychosocial Support Alone (BEHAVIORAL), Sham taVNS (OTHER).
Who is sponsoring clinical trial NCT05866471?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05866471 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05866471's enrollment target sits among peer trials
108 204th of 1090 higher than 884 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI